Table 4
Open in new tab

Univariate and multivariate analyses to identify predictors 1 month after nivolumab initiation for PFS and OS

VariablePFS (n = 38)
Univariate analysisMultivariate analysis
HRP valueHRP value
Post-CRP/pre-CRP
 <1.011
 ≥1.01.283 (0.611–2.693)0.51061.216 (0.568–2.599)0.6417
Post-NLR/pre-NLR
 <1.011
 ≥1.01.285 (0.561–2.944)0.55311.102 (0.470–2.586)0.8230
Post-ALC/pre-ALC
 <1.011
 ≥1.00.408 (0.185–0.900)0.02630.419 (0.189–0.926)0.0317
Post-MLR/pre-MLR
 <1.01
 ≥1.01.043 (0.484–2.250)0.9143
Post-PLR/pre-PLR
 <1.01
 ≥1.01.035 (0.488–2.198)0.9279
VariableOS (n = 38)
Univariate analysisMultivariate analysis
HRP valueHRP value
Post-CRP/pre-CRP
 <1.011
 ≥1.02.044 (0.668–6.255)0.21051.982 (0.642–6.121)0.2346
Post-NLR/pre-NLR
 <1.011
 ≥1.05.014 (0.650–38.657)0.12183.487 (0.442–27.530)0.2361
Post-ALC/pre-ALC
 <1.011
 ≥1.00.252 (0.082–0.781)0.01690.285 (0.091–0.890)0.0308
Post-MLR/pre-MLR
 <1.01
 ≥1.01.985 (0.545–7.222)0.2982
Post-PLR/pre-PLR
 <1.01
 ≥1.01.619 (0.498–5.261)0.4232
VariablePFS (n = 38)
Univariate analysisMultivariate analysis
HRP valueHRP value
Post-CRP/pre-CRP
 <1.011
 ≥1.01.283 (0.611–2.693)0.51061.216 (0.568–2.599)0.6417
Post-NLR/pre-NLR
 <1.011
 ≥1.01.285 (0.561–2.944)0.55311.102 (0.470–2.586)0.8230
Post-ALC/pre-ALC
 <1.011
 ≥1.00.408 (0.185–0.900)0.02630.419 (0.189–0.926)0.0317
Post-MLR/pre-MLR
 <1.01
 ≥1.01.043 (0.484–2.250)0.9143
Post-PLR/pre-PLR
 <1.01
 ≥1.01.035 (0.488–2.198)0.9279
VariableOS (n = 38)
Univariate analysisMultivariate analysis
HRP valueHRP value
Post-CRP/pre-CRP
 <1.011
 ≥1.02.044 (0.668–6.255)0.21051.982 (0.642–6.121)0.2346
Post-NLR/pre-NLR
 <1.011
 ≥1.05.014 (0.650–38.657)0.12183.487 (0.442–27.530)0.2361
Post-ALC/pre-ALC
 <1.011
 ≥1.00.252 (0.082–0.781)0.01690.285 (0.091–0.890)0.0308
Post-MLR/pre-MLR
 <1.01
 ≥1.01.985 (0.545–7.222)0.2982
Post-PLR/pre-PLR
 <1.01
 ≥1.01.619 (0.498–5.261)0.4232

Post, post-1 month from nivolumab initiation; pre, pretreatment.

Table 4
Open in new tab

Univariate and multivariate analyses to identify predictors 1 month after nivolumab initiation for PFS and OS

VariablePFS (n = 38)
Univariate analysisMultivariate analysis
HRP valueHRP value
Post-CRP/pre-CRP
 <1.011
 ≥1.01.283 (0.611–2.693)0.51061.216 (0.568–2.599)0.6417
Post-NLR/pre-NLR
 <1.011
 ≥1.01.285 (0.561–2.944)0.55311.102 (0.470–2.586)0.8230
Post-ALC/pre-ALC
 <1.011
 ≥1.00.408 (0.185–0.900)0.02630.419 (0.189–0.926)0.0317
Post-MLR/pre-MLR
 <1.01
 ≥1.01.043 (0.484–2.250)0.9143
Post-PLR/pre-PLR
 <1.01
 ≥1.01.035 (0.488–2.198)0.9279
VariableOS (n = 38)
Univariate analysisMultivariate analysis
HRP valueHRP value
Post-CRP/pre-CRP
 <1.011
 ≥1.02.044 (0.668–6.255)0.21051.982 (0.642–6.121)0.2346
Post-NLR/pre-NLR
 <1.011
 ≥1.05.014 (0.650–38.657)0.12183.487 (0.442–27.530)0.2361
Post-ALC/pre-ALC
 <1.011
 ≥1.00.252 (0.082–0.781)0.01690.285 (0.091–0.890)0.0308
Post-MLR/pre-MLR
 <1.01
 ≥1.01.985 (0.545–7.222)0.2982
Post-PLR/pre-PLR
 <1.01
 ≥1.01.619 (0.498–5.261)0.4232
VariablePFS (n = 38)
Univariate analysisMultivariate analysis
HRP valueHRP value
Post-CRP/pre-CRP
 <1.011
 ≥1.01.283 (0.611–2.693)0.51061.216 (0.568–2.599)0.6417
Post-NLR/pre-NLR
 <1.011
 ≥1.01.285 (0.561–2.944)0.55311.102 (0.470–2.586)0.8230
Post-ALC/pre-ALC
 <1.011
 ≥1.00.408 (0.185–0.900)0.02630.419 (0.189–0.926)0.0317
Post-MLR/pre-MLR
 <1.01
 ≥1.01.043 (0.484–2.250)0.9143
Post-PLR/pre-PLR
 <1.01
 ≥1.01.035 (0.488–2.198)0.9279
VariableOS (n = 38)
Univariate analysisMultivariate analysis
HRP valueHRP value
Post-CRP/pre-CRP
 <1.011
 ≥1.02.044 (0.668–6.255)0.21051.982 (0.642–6.121)0.2346
Post-NLR/pre-NLR
 <1.011
 ≥1.05.014 (0.650–38.657)0.12183.487 (0.442–27.530)0.2361
Post-ALC/pre-ALC
 <1.011
 ≥1.00.252 (0.082–0.781)0.01690.285 (0.091–0.890)0.0308
Post-MLR/pre-MLR
 <1.01
 ≥1.01.985 (0.545–7.222)0.2982
Post-PLR/pre-PLR
 <1.01
 ≥1.01.619 (0.498–5.261)0.4232

Post, post-1 month from nivolumab initiation; pre, pretreatment.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close